571 related articles for article (PubMed ID: 29243329)
41. Thrombopoietin-receptor agonists.
Basciano PA; Bussel JB
Curr Opin Hematol; 2012 Sep; 19(5):392-8. PubMed ID: 22872157
[TBL] [Abstract][Full Text] [Related]
42. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
43. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
44. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
45. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
[No Abstract] [Full Text] [Related]
46. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
47. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
[TBL] [Abstract][Full Text] [Related]
48. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
49. Positioning new treatments in the management of immune thrombocytopenia.
Arnold DM
Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
[TBL] [Abstract][Full Text] [Related]
50. Face validity of the Kids' ITP Tools (KIT) in the era of thrombopoietin receptor agonists.
McGuire C; Young NL; Livingston J; Dhir V; Blanchette VS; Kirby-Allen M; Klaassen RJ
Pediatr Blood Cancer; 2024 Apr; 71(4):e30888. PubMed ID: 38265264
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Lusa A; Carlson A
Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
[TBL] [Abstract][Full Text] [Related]
52. [Management of refractory ITP with thrombopoietin receptor agonists].
Tomiyama Y
Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
[No Abstract] [Full Text] [Related]
53. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
54. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
[TBL] [Abstract][Full Text] [Related]
55. TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
Rodeghiero F
Am J Hematol; 2012 Oct; 87(10):943. PubMed ID: 22847599
[No Abstract] [Full Text] [Related]
56. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Ayad N; Grace RF; Al-Samkari H
Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
[TBL] [Abstract][Full Text] [Related]
57. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.
Kapur R
Br J Haematol; 2022 Sep; 198(5):803-804. PubMed ID: 35748239
[TBL] [Abstract][Full Text] [Related]
58. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
59. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
